India revokes GSK patent on breast cancer drug Tykerb

India's patent appeals board has revoked a patent granted to GlaxoSmithKline Plc's breast cancer drug Tykerb, which is a salt form of the original compound, lapatinib.

FP Archives|Dec 20, 2014, 22:35:45 IST

Mumbai: India's patent appeals board has revoked a patent granted to GlaxoSmithKline Plc's breast cancer drug Tykerb, which is a salt form of the original compound, lapatinib.

However, the Intellectual Property Appellate Board (IPAB) upheld a patent granted to the original compound, or active pharmaceutical ingredient, citing innovative merit.

Fresenius Kabi Oncology , the Indian unit of German healthcare group Fresenius SE , had challenged patents granted for both the original molecule and it's marketed version Tykerb, saying both molecules lacked innovation.

"We are studying the IPAB's decision but maintain our belief in the inventiveness of the lapatinib ditosylate salt and will consider the possibility of taking further steps before the appropriate authorities to validate this," the Indian unit of UK-based GSK said in an email to Reuters on Friday.

The IPAB orders for both the patent disputes were uploaded on its website late on Thursday.

BOJ seen raising interest rates by December as weak yen fuels inflation risks

Majority of economists expect Japan's central bank to deliver a 25-basis-point rate hike by year-end, with further policy tightening likely through 2027.

2 min read

'From make in India to launch from India': Skyroot COO on why Vikram-1 could change India’s space sector

Skyroot Aerospace’s successful Vikram-1 mission marks a major milestone for India’s private space sector, as the country seeks to shift from “Make in India” to “Launch from India” and compete in the global commercial satellite launch market

8 min read

Google burns cash for first time as AI spending pushes 2026 capex to $205 billion

Google parent Alphabet reported negative free cash flow of $5.9 billion in the second quarter for the first time since going public, as surging AI infrastructure spending pushed its 2026 capital expenditure forecast to as much as $205 billion

6 min read

Tesla sells more cars but makes less money: Why Musk’s AI pivot is squeezing profits

Tesla’s record Q2 deliveries failed to translate into higher profits as price cuts, falling regulatory-credit revenue and Elon Musk’s aggressive AI spending squeezed margins and pushed the EV maker into negative free cash flow

5 min read

No premium queues, 30-minute target: What changes for Indian passport applicants in UAE

Indian passport applicants in the UAE can now access passport, visa and attestation services through Alhind’s 16 centres, with no premium queues, a Dh19 service fee and a target of completing applications within 30 minutes

4 min read

Up Next